Singapore's import value of blood, antisera, vaccines, toxins, and cultures stood at USD 751.31 million in 2023. Over the past decade, the market has shown considerable fluctuations with an overall upward trend. The largest annual increase was in 2018, with a rise of over 52%. However, there were periods of decline, notably in 2017 and 2022. The compounded annual growth rate (CAGR) over the last five years is 3.08%. Moving forward, the forecast suggests a continued increase, with the market expected to reach USD 899.66 million by 2028, reflecting a CAGR of 2.72% for the next five years.

Future trends to watch for:

Increased demand for healthcare products due to aging populations and global health crises.
Innovation and advancements in biotechnology and pharmaceuticals driving market growth.
Geopolitical factors and trade policies potentially impacting supply chains and import patterns.
Adoption of new healthcare policies and regulations.